{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:10:27Z","timestamp":1785586227019,"version":"3.56.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oclacitinib is a novel Janus kinase (JAK) inhibitor that potently inhibits JAK1\u2010dependent cytokines involved in allergy, inflammation, and pruritus (IL\u20102, IL\u20104, IL\u20106, IL\u201013, and IL\u201031). Oclacitinib (Apoquel\u00ae, Zoetis Inc, Parsippany, NJ) is approved for the treatment\/control of pruritus associated with allergic dermatitis and treatment\/control of clinical manifestations of atopic dermatitis in dogs at least 12\u2009months of age. To evaluate the effectiveness of oclacitinib in dogs with flea allergy dermatitis, the JAK1 selective inhibitor was tested in a placebo\u2010controlled, masked, single\u2010dose (0.4\u2009mg\/kg) or repeat\u2010dose (0.4\u2009mg\/kg, twice daily for 2\u2009weeks) study. Pruritic behaviors were quantitated by video recording, and erythema and skin lesions were assessed using a 10\u2010cm visual analog scale (VAS). Results showed that oclacitinib reduced pruritus by 61% as early as 1.5\u2009h after a single oral dose compared to placebo, with an average reduction (compared to placebo) of 85% 1\u20135\u2009h after dosing (0.4\u2009mg\/kg; <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001). Oclacitinib also significantly reduced erythema (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001) and skin lesion (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0005) VAS scores on Day 14 compared to placebo in a repeat dose study. No adverse events were noted during the conduct of these studies. IL\u201031 concentrations were elevated in the majority of dogs after flea infestation, suggesting JAK1\u2010dependent cytokines may drive clinical signs of flea allergy dermatitis. These findings show that oclacitinib, an inhibitor of JAK1\u2010dependent cytokines involved in allergy and inflammation can rapidly reduce clinical signs associated with flea allergic dermatitis in dogs.<\/jats:p>","DOI":"10.1111\/jvp.13462","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:25:25Z","timestamp":1719462325000},"page":"447-453","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oclacitinib (<scp>APOQUEL<\/scp>\u00ae) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-5825","authenticated-orcid":false,"given":"Andrea J.","family":"Gonzales","sequence":"first","affiliation":[{"name":"Veterinary Medicine Research and Development Zoetis  Kalamazoo Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Aleo","sequence":"additional","affiliation":[{"name":"Veterinary Medicine Research and Development Zoetis  Kalamazoo Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Mahabir","sequence":"additional","affiliation":[{"name":"Veterinary Medicine Research and Development Zoetis  Kalamazoo Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Messamore","sequence":"additional","affiliation":[{"name":"Veterinary Medicine Research and Development Zoetis  Kalamazoo Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Veterinary Medicine Research and Development Zoetis  Zaventem Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00716.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12087"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12166"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12101"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01098.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12887"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568010023344661"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.106"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2427(99)00057-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110340"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12740"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-015-0514-6"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901860"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.1.51.pe55"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.13462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T01:18:35Z","timestamp":1731374315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.13462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/jvp.13462"],"URL":"https:\/\/doi.org\/10.1111\/jvp.13462","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"2024-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}